We found that at baseline, those who subsequently developed CM-IRIS showed a characteristically lower immune response with decreased CD4+IFN-γ+ T cells and poor CD8+IL-17+ mitogenic responses at CM-IRIS. This evidence concerns the gene CD4 and cutaneous mastocytosis.